Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial
"These results are promising particularly because they show the potential…
8 October 2013 | By Boehringer Ingelheim
"These results are promising particularly because they show the potential to evaluate harder-to-treat populations..."